Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd. announced several changes to its Board of Directors and committee assignments. Gwen Melincoff was appointed as a Class I Director and will chair the Nominating and Governance Committee. Concurrently, Claude Nicaise and Jill Quigley resigned from their positions as directors and members of the Audit Committee. Neil Cohen and Dr. Nissim Darvish were appointed to the Audit Committee, with Mr. Cohen also resigning from his role as Chair of the Nominating Committee. Following these changes, the Board will comprise five directors.

Chemomab Therapeutics announced its first quarter 2026 financial results, reporting a net loss of $1.8 million. The company also provided a corporate update, highlighting new clinical and translational data for nebokitug presented at Digestive Disease Week 2026 and upcoming presentations at EASL Congress 2026. These studies further confirm nebokitug's disease-modifying potential in Primary Sclerosing Cholangitis (PSC) and suggest possible additional benefits for PSC patients with co-existing Inflammatory Bowel Disease (IBD). Chemomab continues to pursue multiple partnering options for nebokitug.

Chemomab Therapeutics announced new clinical and translational data for nebokitug, presented at major medical meetings, further confirming its disease-modifying potential in Primary Sclerosing Cholangitis (PSC) and suggesting additional benefits for PSC patients with co-existing Inflammatory Bowel Disease (IBD). The company continues to advance multiple partnering options for nebokitug. For Q1 2026, Chemomab reported a net loss of $1.8 million, an improvement from $3.3 million in Q1 2025, with cash reserves of $8.0 million expected to fund operations through Q1 2027.

Chemomab Therapeutics Ltd. announced the results of its annual general shareholders meeting, which was held on May 5, 2026. Shareholders approved the re-election of Mr. Neil Cohen and Dr. Claude Nicaise as Class II directors. Key proposals also approved included the compensation policy for office holders and directors, an increase in the company's authorized share capital, and the re-appointment of Somekh Chaikin (KPMG) as the independent registered public accounting firm for the fiscal year ended December 31, 2026.

Chemomab Therapeutics Ltd. announced the adjournment of its Annual General Meeting of Shareholders (AGM) from April 28, 2026, to May 5, 2026. The meeting was postponed due to a lack of quorum. The time and location for the rescheduled meeting remain unchanged. Further details regarding the proposed resolutions were previously provided in a proxy statement filed on March 20, 2026.